Drug Profile
Genopep 1
Alternative Names: GNP 1; IS-107; ISSAR 1Latest Information Update: 19 Apr 2023
Price :
$50
*
At a glance
- Originator Issar Pharma
- Class Antineoplastics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 19 Apr 2023 Issar Pharmaceuticals plans a phase II trial dossier for Solid tumours in India (Issar Pharmaceuticals pipeline, April 2023)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in India (IV, Infusion)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in India (SC)